Breaking News
Get 50% Off 0
Get a powerful boost to your portfolio: August's freshest AI-picked stocks
Pick Stocks with AI
Close

ADDvise Group AB B (ADDVb)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.412 -0.004    -0.28%
09:05:09 - Real-time Data. Currency in SEK
Type:  Equity
Market:  Sweden
ISIN:  SE0007464862 
S/N:  583209491
  • Volume: 3,141
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.392 - 1.412
ADDvise Group AB B 1.412 -0.004 -0.28%

ADDvise Group AB B Company Profile

 
Get an in-depth profile of ADDvise Group AB B, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryHealthcare Equipment & Supplies
SectorHealthcare
Employees

641

Equity Type

ORD

ADDvise Group AB (publ) supplies medical devices, equipment, and consumables to public and private laboratories and research facilities, healthcare, and pharmaceuticals in North America, Europe, South America, Sweden, and internationally. The company provides laboratory furniture, protective ventilation systems, climate-controlled clean rooms, and laboratory equipment; and develops and supplies medical equipment, consumables, and pharmaceuticals in areas, such as urology, gynecology, emergency care, and surgery. It is also involved in rental and sale of medical equipment; distributes specialized instruments, consumables, and services in the life-science and biopharma sectors; designing, constructing, and installing customized cleanrooms and air conditioning systems; distributes glucose monitors and insulin pumps for diabetic patients; develops, manufactures, and markets products for rescue, ambulance, healthcare, and rehabilitation operations. In addition, the company offers implants, instruments, and technologies for surgical precision and patient; disposable medical devices, cables, connectors, wires, CO2 indicators, ultrasound device, patient positioning equipment, and surgical tables; develops software and instruments for patient mobility, pain, and muscle strength to rehabilitate muscular conditions, as well as to streamline the monitoring of vital signs in patients in long-term care and nursing homes; operates mail-order pharmacy specializing in men’s health medications for treating cancer, incontinence, and impotence; develops, manufactures, and markets over-the-counter generic drugs for pain management and for the treatment of coughs, colds, allergies, sinus infections, and urological conditions; and supplies glucose meter and test strip products. The company was formerly known as ADDvise Lab Solutions AB (publ). ADDvise Group AB (publ) was founded in 1989 and is headquartered in Stockholm, Sweden.

Contact Information

Address Grev Turegatan 30
Stockholm, 114 38
Sweden
Phone 46 8 12 87 66 00
Fax -

Top Executives

Name Age Since Title
Fredrik Celsing 57 2016 Independent Chairman
Thomas Eklund - 2024 Director
Richard Akhtarzand 53 2010 Director
Anna Ljung 45 2022 Director
Johanne Louise Braendgaard 51 2021 Independent Director
Thomas Eklund 58 2024 Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ADDVb Comments

Write your thoughts about ADDvise Group AB B
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email